

What is claimed is:

Sub a3 1. A method of predicting the lymphotropic metastatic potential of a solid non-lymphoid tumor, the method comprising obtaining a plurality of representative samples of the tumor and determining the percentage of cells of each of the samples which express lymphoid gene products, wherein the metastatic potential of the tumor is predicted to be low when no tumor cells in all of the samples are detected to express lymphoid gene products and predicted to be high when a high percentage of the tumor cells in at least one of the samples are detected to express lymphoid gene products.

2. A method of treating a solid non-lymphoid tumor, the method comprising systemically administering a substance comprising a therapeutically effective amount of a molecule linked to a toxin, radionuclide, or chemotherapeutic agent and having binding specificity for a tumor specific lymphoid gene product idiotype.

3. A method according to claim 2 further comprising selecting the molecule to be a cell permeable non-peptide ZAP-70 antagonist.

4. A method according to claim 2 further comprising selecting the molecule to be an anti-ZAP-70 antibody and/or anti-SYK-B antibody.

5. A method of predicting the lymphotropic metastatic potential of a primary solid non-lymphoid tumor, the method comprising sub-cutaneously injecting cells from the tumor into at least one anti-AsGMI-treated nude animal and examining the animal for tumors at sites other than the site of the injection.